Inhibition of heat shock protein 90 alleviates cholestatic liver injury by decreasing IL‑1β and IL‑18 expression
Open Access
- 21 January 2021
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (3) , 1
Abstract
Severe cholestatic liver injury diseases, such as obstructive jaundice and the subsequent acute obstructive cholangitis, are induced by biliary tract occlusion. Heat shock protein 90 (HSP90) inhibitors have been demonstrated to be protective for various organs. The potential of HSP90 inhibitors in the treatment of cholestatic liver injury, however, remains unclear. In the present study, rat models of bile duct ligation (BDL) were established, the HSP90 inhibitor 17‑dimethylamino‑ethylamino‑17‑demethoxygeldanamycin (17‑DMAG) was administered, and its ability to ameliorate the cholestasis‑induced liver injuries was evaluated. In the BDL rat models and clinical samples, increased HSP90 expression was observed to be associated with cholestatic liver injury. Furthermore, 17‑DMAG alleviated cholestasis‑induced liver injury in the rat models, as revealed by the assessment of pathological changes and liver function. In addition, 17‑DMAG protected hepatocytes against cholestatic injury in vitro. Further assays indicated that 17‑DMAG administration prevented cholestasis‑induced liver injury in the rats by decreasing the expression of interleukin (IL)‑1β and IL‑18. Moreover, 17‑DMAG also decreased the cholestasis‑induced upregulation of IL‑1β and IL‑18 in liver sinusoidal endothelial cells in vitro. In conclusion, the HSP90 inhibitor 17‑DMAG is able to prevent liver injury in rats with biliary obstruction, and this phenomenon is associated with the reduction of IL‑1β and IL‑18 expression.Keywords
This publication has 51 references indexed in Scilit:
- Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in miceHepatology, 2011
- The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Journal of Hematology & Oncology, 2010
- Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperoneNature Communications, 2010
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2010
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaLeukemia, 2010
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesEuropean Journal of Cancer, 2010
- Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasomeJournal of Clinical Investigation, 2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001
- Geldanamycin Induces Heat Shock Protein Expression Through Activation of HSF1 in K562 Erythroleukemic CellsIUBMB Life, 1999